Mesoblast (MESO) Competitors $17.95 +0.16 (+0.90%) Closing price 04:00 PM EasternExtended Trading$17.75 -0.20 (-1.11%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. VRNA, RVMD, MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, and NUVLShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Its Competitors Verona Pharma PLC American Depositary Share Revolution Medicines Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Abivax CRISPR Therapeutics Nuvalent Mesoblast (NASDAQ:MESO) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation. Do analysts rate MESO or VRNA? Mesoblast presently has a consensus price target of $24.00, suggesting a potential upside of 33.70%. Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, suggesting a potential upside of 1.95%. Given Mesoblast's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mesoblast is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.80Verona Pharma PLC American Depositary Share 1 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.07 Do institutionals & insiders have more ownership in MESO or VRNA? 1.4% of Mesoblast shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to MESO or VRNA? In the previous week, Mesoblast and Mesoblast both had 3 articles in the media. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.17 beat Mesoblast's score of 0.62 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, MESO or VRNA? Mesoblast has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Which has better earnings and valuation, MESO or VRNA? Mesoblast has higher earnings, but lower revenue than Verona Pharma PLC American Depositary Share. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$17.20M133.59-$102.14MN/AN/AVerona Pharma PLC American Depositary Share$42.28M217.94-$173.42M-$0.99-107.99 Is MESO or VRNA more profitable? Mesoblast has a net margin of 0.00% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Mesoblast's return on equity of 0.00% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% SummaryMesoblast beats Verona Pharma PLC American Depositary Share on 9 of the 14 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.28B$3.37B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E RatioN/A22.7785.3627.36Price / Sales133.59485.21607.16135.99Price / CashN/A46.7037.4661.86Price / Book3.8410.5512.426.81Net Income-$102.14M-$52.58M$3.32B$276.80M7 Day Performance-9.11%1.09%1.01%0.27%1 Month Performance16.11%16.09%10.75%8.31%1 Year Performance86.59%18.41%76.20%35.60% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast1.9573 of 5 stars$17.95+0.9%$24.00+33.7%+79.2%$2.28B$17.20M0.0080VRNAVerona Pharma PLC American Depositary Share1.4526 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.1276 of 5 stars$46.58-0.3%$74.64+60.2%-3.5%$8.73B$11.58M-10.35250Analyst ForecastInsider TradeMRUSMerus0.889 of 5 stars$94.270.0%$93.12-1.2%+81.8%$7.13B$56.23M-17.1437RNAAvidity Biosciences2.0042 of 5 stars$46.18-1.7%$68.32+47.9%+3.0%$6.86B$10.90M-12.97190GRFSGrifols3.7642 of 5 stars$9.61-3.4%$10.30+7.2%+11.7%$6.84B$7.81B8.2123,822Positive NewsCYTKCytokinetics3.5724 of 5 stars$60.64+6.4%$76.64+26.4%+12.0%$6.82B$18.47M-11.89250RYTMRhythm Pharmaceuticals3.0481 of 5 stars$97.86-1.2%$106.64+9.0%+109.4%$6.58B$130.13M-32.51140ABVXAbivax2.8443 of 5 stars$86.67+3.3%$103.29+19.2%+925.4%$6.34BN/A0.0061Analyst ForecastHigh Trading VolumeCRSPCRISPR Therapeutics1.5559 of 5 stars$70.19+3.6%$71.50+1.9%+45.1%$6.16B$37.31M-12.93460Analyst ForecastInsider TradeNUVLNuvalent2.9334 of 5 stars$83.85-0.4%$118.89+41.8%-18.0%$6.07BN/A-17.1140News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies VRNA Competitors RVMD Competitors MRUS Competitors RNA Competitors GRFS Competitors CYTK Competitors RYTM Competitors ABVX Competitors CRSP Competitors NUVL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
